

BMJ Open Seeking the source of *Pseudomonas aeruginosa* infections in a recently opened hospital: an observational study using whole-genome sequencing

Joshua Quick,^{1,2} Nicola Cumley,² Christopher M Wearn,^{2,3} Marc Niebel,² Chrystala Constantinidou,⁴ Chris M Thomas,¹ Mark J Pallen,⁴ Naiem S Moiemien,^{2,3} Amy Bamford,^{2,3} Beryl Oppenheim,² Nicholas J Loman¹

To cite: Quick J, Cumley N, Wearn CM, *et al.* Seeking the source of *Pseudomonas aeruginosa* infections in a recently opened hospital: an observational study using whole-genome sequencing. *BMJ Open* 2014;**4**:e006278. doi:10.1136/bmjopen-2014-006278

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-006278>).

JQ and NC contributed equally.

Received 1 August 2014
Revised 16 September 2014
Accepted 26 September 2014



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Nicholas James Loman;
n.j.loman@bham.ac.uk
or Dr Beryl Oppenheim;
Beryl.Oppenheim@uhb.nhs.uk

ABSTRACT

Objectives: *Pseudomonas aeruginosa* is a common nosocomial pathogen responsible for significant morbidity and mortality internationally. Patients may become colonised or infected with *P. aeruginosa* after exposure to contaminated sources within the hospital environment. The aim of this study was to determine whether whole-genome sequencing (WGS) can be used to determine the source in a cohort of burns patients at high risk of *P. aeruginosa* acquisition.

Study design: An observational prospective cohort study.

Setting: Burns care ward and critical care ward in the UK.

Participants: Patients with >7% total burns by surface area were recruited into the study.

Methods: All patients were screened for *P. aeruginosa* on admission and samples taken from their immediate environment, including water. Screening patients who subsequently developed a positive *P. aeruginosa* microbiology result were subject to enhanced environmental surveillance. All isolates of *P. aeruginosa* were genome sequenced. Sequence analysis looked at similarity and relatedness between isolates.

Results: WGS for 141 *P. aeruginosa* isolates were obtained from patients, hospital water and the ward environment. Phylogenetic analysis revealed eight distinct clades, with a single clade representing the majority of environmental isolates in the burns unit. Isolates from three patients had identical genotypes compared with water isolates from the same room. There was clear clustering of water isolates by room and outlet, allowing the source of acquisitions to be unambiguously identified. Whole-genome shotgun sequencing of biofilm DNA extracted from a thermostatic mixer valve revealed this was the source of a *P. aeruginosa* subpopulation previously detected in water. In the remaining two cases there was no clear link to the hospital environment.

Conclusions: This study reveals that WGS can be used for source tracking of *P. aeruginosa* in a hospital setting, and that acquisitions can be traced to a specific source within a hospital ward.

Strengths and limitations of this study

- We have demonstrated that whole-genome sequencing can be used for source tracking of *Pseudomonas aeruginosa* in a hospital setting.
- We show convincing evidence that transmission has occurred directly from water to patients, but other routes are as likely.
- The main limitation of the study was the sample size, which could be attributable to interventions being carried out during the study.
- Our study focused on a burns unit and critical care unit in a newly built hospital. Modes of *P. aeruginosa* transmission may be different in hospitals with different styles of plumbing and on other augmented care units.

INTRODUCTION

Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium and an important opportunistic pathogen in the healthcare setting. *P. aeruginosa* particularly affects those with impaired host or mucosal immunity and has a broad range of presentations including respiratory infections in cystic fibrosis and mechanically ventilated patients, bloodstream infections in premature neonates and wounds in burns injuries. Nosocomial *P. aeruginosa* outbreaks are frequently reported and associated with water sources such as taps, showers, mixer valves and flow straighteners, sink traps and drains.^{1–10} Other potential routes of transmission include cross-infection, for example, carriage on the hands of healthcare workers, and through contaminated medical equipment such as endoscopic devices.^{3 5}

In the UK, the role of water in the transmission of *P. aeruginosa* in healthcare settings has become a matter of urgent concern in response to a recent high-profile outbreak

affecting a neonatal critical care unit in Belfast in 2012.¹¹ This source was eventually determined to be sink taps.^{11–13} National guidance is now in place detailing enhanced procedures for routine water sampling on augmented care units, with directed interventions such as disinfection and replacement of high-risk plumbing parts required.¹⁴

Historical phenotypic typing methods for *P. aeruginosa* such as O-antigen serotyping have more recently been replaced by molecular typing methods such as pulsed-field gel electrophoresis (PFGE), variable number tandem repeat analysis, random amplification of polymorphic DNA and multilocus sequencing typing (MLST).¹⁵ These methods have been used to investigate outbreaks of *P. aeruginosa* within hospitals.^{4 16–18} However, such techniques have important limitations for source tracking of infections in hospitals as they sample limited numbers of sites in the genome which may result in false clustering of unrelated strains.¹⁹ In the past 5 years, whole-genome sequencing (WGS) has started to be used to investigate outbreaks in hospitals. WGS is attractive because of its digital, sharable format and ultra-high resolution, which is able to discriminate two isolates differing by just a single mutation. WGS has been successfully used to determine likely transmission chains during outbreaks of *Staphylococcus aureus*, *Acinetobacter baumannii* and *Klebsiella pneumoniae*.^{19–21} Benchtop sequencing instruments now offer a cost-effective approach for bringing bacterial WGS to the clinical environment.²²

In this study, we explore the utility of WGS to determine the likely sources of *P. aeruginosa* in an at-risk population of burns patients. In the UK and US burns patients receive shower cart hydrotherapy as a mainstay of burns treatment.^{23–26} A previous hospital audit suggested that up to one-third of such patients became colonised with *P. aeruginosa*. We hypothesised that this high rate of acquisition may relate to transmission from hospital shower water during therapy. We therefore wished to understand the importance of transmission from water compared with alternative routes such as cross-infection and endogenous carriage.

MATERIALS AND METHODS

Hospital setting

An observational, prospective study design was employed in a burns centre serving approximately 13.7 million people across the Midlands region of England with 300 admissions annually. Opened in June 2010, the burns centre comprises a purpose built 15-bed ward with 11 side-rooms and 2 dual-bedded rooms. Patients requiring mechanical ventilation and organ support are usually treated in two self-contained burns cubicles located within the trauma critical care unit. Despite the observational nature of the study, sampling was carried out during implementation of interim national guidance on control of *P. aeruginosa* issued by the Department of

Health. These guidelines were issued in draft form March 2012, and subsequently revised in March 2013. This meant that parallel water sampling and engineering interventions were being undertaken during the period of study. In addition, some enhanced infection prevention measures were also introduced in response to an outbreak of a multidrug-resistant *A. baumannii*.

Study design and patient selection

Patients admitted to the burns unit were eligible for the screening phase of the study if they had burns injuries covering greater than 7% total body surface area (TBSA). Patients were screened as soon as possible after admission after they had given written informed consent. When appropriate, legal consultee advice was sought for patients lacking capacity due to emergency treatment. On admission, recruited patients were screened for carriage of *P. aeruginosa* (wounds, urine and stool) using standard microbiology techniques. Samples were then taken as part of routine microbiology service during the patients stay. Environmental and water samples were taken after the patient was admitted to the burns centre. If during the period of stay *P. aeruginosa* was isolated from a patient sample the patient was recruited into the second phase of the study. In this phase, patients had wound swabs taken at each dressing change as well as twice-weekly urine samples. The patient's environment and water from outlets in their bed space were sampled weekly for the duration of their stay, and after discharge (post-cleaning). Termination of the study was planned after 30 screening patient admissions, or a year, whichever came soonest, after which 10 patients were expected to acquire *P. aeruginosa*. This prediction was based on a previous local audit which suggested about one-thirds of burns patients became colonised with *P. aeruginosa*.

Microbiological and molecular methods

P. aeruginosa isolates were obtained from wound swab, urine, stool, environmental and water samples. *P. aeruginosa* was isolated from wound swabs, urine and stool by inoculation onto cysteine lactose electrolyte deficient agar (CLED) and cetrimide agar and incubation for 24 h at 37°C. Stool samples were cultured overnight in a cetrimide enrichment broth before subculture onto CLED. Identification was confirmed by resistance to C-390 and the VITEK 2 GN identification card. Antibiotic sensitivity assays were performed using the VITEK 2 AST N-210 card (bioMérieux, Basingstoke, UK).

The patient's environment (shower head rosette, drain, shower chair or trolley, bedside table, patient chair, instruments in contact with the patient) was sampled over a 10 cm² area by a Polywipe sponge. The sponge was placed in tryptic soy broth incubated for 24 h at 37°C then subcultured onto CLED and cetrimide agar. During water sampling, water was taken from the patient's shower, or tap if a shower was not present. Shower heads were not removed for water sampling. At

least 200 mL of water was collected into a vessel containing sodium thiosulfate as a neutraliser. In duplicate, 100 mL of water was filtered through a 0.45 µ filter and the filters placed onto CLED plates and cetrimide agar. Plates were incubated at 37°C for 48 h and the number of organisms per 100 mL quantified.

For storage and DNA extraction a single colony was purified from the primary culture plate. When different colony morphologies were observed, a single colony from each type was purified. Additionally, for a randomly selected water sample, 24 colonies were individually picked from one water-filter primary microbiological plate for sequencing. Isolates were stored on Biobank beads at -20°C prior to DNA extraction. Organisms were resuscitated on CLED agar plates and genome DNA either extracted directly using the MOBIO UltraClean Microbial DNA Kit, or from overnight LB broth culture using a Qiagen Genomic-Tip 100G.

DNA extraction and sequencing

Genomic DNA was prepared from single colony picks using the MOBIO Ultraclean microbial kit (MOBIO, Carlsbad, USA). 1 ng input DNA, as quantified by Qubit (Life Technologies, Carlsbad, USA) was used to prepare genomic libraries for sequencing using the Illumina Nextera XT DNA sample kit as per manufacturer's protocol (Illumina, San Diego, USA). Libraries were sequenced on the Illumina MiSeq using a paired-end protocol resulting in read lengths between 150 and 300 bases. A single additional sample, isolate 910, was chosen as a representative member of Clade 5 for long-read sequencing. DNA from this sample was fragmented using a Hydroshear (Digilab, Marlborough, Massachusetts, USA) using the recommended protocol for 10 kb fragments and further size-selected on a BluePippin instrument (Sage Science, Massachusetts, USA) with a 7 kb minimum size cut-off. The library was sequenced on two SMRT Cells using the Pacific Biosciences RS II instrument at the Norwegian Sequencing Centre, Oslo. C4-P2 chemistry was chosen because it favours long, more accurate reads for *de novo* assembly.

Stool PCR

For simple presence/absence detection of *P. aeruginosa* in stool samples using PCR, a stool sample was collected into a stool collection tube containing stool DNA stabiliser. Total DNA was extracted using the PSP Spin Stool DNA Plus kit (Strattec Molecular). PCR amplification of species specific regions of the 16S rDNA gene was carried out using primers PA-SS-F: GGGGGATCTTCG GACCTCA and PA-SS-R: TCCTTAGAGTGTCCACCCG¹² in the following conditions: 0.5 µM of each primer, 1.5 mM MgCl₂, 0.2 mM dNTP's using BIOTAQ DNA Polymerase and buffer set. After initial denaturation at 96°C for 2 min, 30 cycles of 96°C for 30 s, 62°C for 30 s and 72°C for 30 s were completed with a final extension of 72°C for 5 min. Products were visualised for size on an 1.5% agarose gel.

Bioinformatics methods

Illumina MiSeq reads from each isolate were adapter and quality trimmed before use with Trimmomatic.²⁷ Phylogenetic reconstruction of isolates sequenced in this study were combined with data from a global collection of 55 *P. aeruginosa* strains collected world-wide which have been previously analysed by Stewart *et al.*²⁸ For each of the published strains, 600 000 paired-end reads of length 250 bases were simulated using wgsim (<https://github.com/lh3/wgsim>) from the complete or draft genome assembly deposited in Genbank. Read sets were mapped against the *P. aeruginosa* PAO1 reference genome using BWA-MEM 0.7.5a-r405 using default settings.²⁹ Single nucleotide polymorphisms were called using VarScan 2.3.6 and filtered for regions with an excessive number of variants. These may represent regions of recombination, misalignments or strong Darwinian selection.³⁰ FastTree (V2.1.7) was used for phylogenetic reconstruction. This software estimates an approximate maximum-likelihood tree under the Jukes-Cantor model of nucleotide evolution with a single rate for each site (CAT).³¹ Trees were drawn in FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>).

For *in silico* MLST prediction, trimmed reads were assembled *de novo* using Velvet³² with a k-mer size of 81 and searched using nucleotide BLAST against the multi-locus sequence database downloaded from the pubMLST website on 5 August 2013 (<http://pubmlst.org/paeruginosa/>).³³ For Clade E isolates, in order to exhaustively search for discriminatory mutations, a nearly complete reference genome was generated by *de novo* assembly using Pacific Biosciences sequencing data. Reads were assembled using the 'RS_HGAP_Assembly.3' pipeline within SMRT Portal V2.2.0. Illumina reads from the same sample were mapped to this draft genome assembly in order to correct remaining indel errors in the assembly using Pilon (<http://www.broadinstitute.org/software/pilon/>). Isolates belonging to each clade were mapped individually against either the PacBio reference (Clade E) or *P. aeruginosa* PAO1 (NC_002516; Clades C, D and G).

Variants (single nucleotide polymorphisms and short insertion-deletions) were called using SAMtools mpileup and VarScan with an allele frequency threshold of 80%.³⁰ Non-informative positions and regions of putative recombination were removed, the later with a variant density filter of more than 3 SNPs every 1000 nucleotides. Analysing samples in each clade individually maximised the number of variants detected by reducing the likelihood of the position being uncovered by a subset of samples. From these variants fine-grained phylogenetic trees were reconstructed for each clade using FastTree. The scripts used to perform this analysis are available at http://www.github.com/joshquick/snp_calling_scripts. Approximate-maximum-likelihood phylogenetic trees were generated using FastTree and visualised in FigTree. For whole-genome shotgun metagenomics analysis, reads were analysed using the Kraken taxonomic classifier

software with the supplied *minikraken* database.³⁴ Reads from the metagenomics data set were aligned to *P. aeruginosa* Clade E as in the previous section and phylogenetic placement was carried out using pplacer in conjunction with FastTree.³⁵ Sequence data is available from the European Nucleotide Archive for the Illumina data (ERP006056) and the corrected Pacific Biosciences assembly (ERP006058).

RESULTS

Study results

Recruitment lasted a period of 300 days, ending according to protocol after the enrolment of 30 screening patients. In total, we detected *P. aeruginosa* in five patients. Of these patients, three had *P. aeruginosa* detected only in burns wound swabs, one had *P. aeruginosa* detected in their burns wound and in their urine, and one had *P. aeruginosa* in their sputum. One additional eligible patient did not consent to enter the study and was excluded. The average age in the study group was 41 years. Males predominated with a male-to-female ratio of 2.3:1. Flame burns were the most common mechanism of injury, followed by scalds and mixed flame/flash injuries. The average burn size of the study group was 12.5% of the TBSA and 27% of patients sustained an inhalation injury. Eight patients required admission to intensive trauma unit (ITU) and the majority required surgical treatment of their burns with excision and skin grafting (80%). A large majority of the study group (83%) received shower cart hydrotherapy as a routine part of their wound management to encourage healing through wound debridement and decontamination. The average length of hospital stay (LOS) was 17 days and taking into account burn size, the average was 1.4 days per % TBSA.

The water and environment in burns and critical care units are frequently colonised by *P. aeruginosa*

A total of 282 water and environmental samples were screened for *P. aeruginosa* of which 39/78 (50%) were positive in water samples, 25/96 (26%) were positive from the wet environment and 7/108 (6%) were positive from the dry environment. A total of 86 genome sequences were generated from the 71 positives, as in some cases multiple colony picks were sequenced. Seventy-eight patient samples were screened for *P. aeruginosa* of which 39 (50%) were positive. A total of 55 genome sequences were generated, as in some cases multiple colony picks were sequenced. In total, 141 genomes were sequenced; water and environmental (n=86) and patient (n=55). Genomes were sequenced to a mean coverage of 24.4x, with the minimum coverage of a sample being 14x and highest 64.7x.

When placed in the context of a global collection of *P. aeruginosa* strains, phylogenetic reconstruction demonstrated isolates in our study fell into eight clades (figure 1A). As has been reported previously, there was no

strong association between ecological context and position in the phylogenetic tree.²⁸ Isolates in this study are most closely related to strains from a variety of settings. The majority of isolates (52%) belong to Clade E (figure 1B), whose nearest sequenced relative is the Liverpool Epidemic Strain, a clone often isolated from patients in the UK and Canada with cystic fibrosis.^{36 37} Isolates from Clade E were found in the burns unit's water and the ward environment, as well as from two patient's wounds. However it was never detected in the critical care unit. Clade E was detected throughout the study in a total of 10 different rooms (figure 2).

Inferring potential transmission events by WGS

Microevolutionary changes occurring over rapid time-scales (ie, days to months) have been used to detect potential chains of transmission in hospital and community outbreaks.^{19–21 38 39} The number of distinct mutations between given isolates has been used to infer whether transmission events are likely to have occurred. Such inferences are aided by prior knowledge of mutation rates in similar populations. Two patients (1 and 4) in our study both had *P. aeruginosa* from Clade E isolated from their wounds. These isolates had an indistinguishable genotype from those present in water and the environment of the room they were nursed within (figures 1C and 3). This genotype was detected in the patient's shower water after initial patient screening, during screening of the second patient admission, twice during the second patient's stay and then 127 days later (days 27, 65, 89 and 216, respectively). When water isolates were positive, the genotype was also detected in wet environment sites (shower drain, shower rosette and patient's trolley) on the same days.

Patient 5 was nursed on the critical care unit due to concomitant medical problems. *P. aeruginosa* belonging to Clade G was isolated from sputum during this time. Identical genotypes were detected contemporaneously in the water from the associated sink and sink tap handle (see online supplementary appendix 4).

Two further patients (patients 2 and 3) were positive for *P. aeruginosa*. Isolates from these patients belonged to Clade C and D, respectively. Neither clade was ever isolated from hospital water. In both cases, identical genotypes were detectable in the environment associated with the patient but these were not detected before or after the patients' stay, indicating that the environment was not persistently contaminated. During the course of patient 3's stay, the dry environment such as the bedside table was contaminated, as was the patient's door handle and shower chair. However, after patient discharge, the strain associated with this patient was never seen again during the course of the study in any location.

WGS permits source tracking of *P. aeruginosa* to individual water outlets

WGS has been reported previously for source tracking, but never for the detection of transmission events from




Figure 1 An overview of all samples collected during the study in global phylogenetic context with other sequenced strains of *Pseudomonas aeruginosa* from the set of Stewart *et al.*²⁸ Samples collected in this study are widely dispersed in the tree, which contains isolates from different environments (A). Bar plots indicate the numbers of each type of sample collected (B). Microdiversity within each clade is shown, with the colour bar indicating the source of each sample (C).

hospital water.⁴⁰ Phylogenetic reconstruction within Clade E, the most commonly detected water clone demonstrated additional diversity within this clone, with a total of 46 mutations detected an average genetic distance between isolates of 4.1 mutations (figure 3). The reconstruction demonstrated clear evidence of clustering of genotypes both by room and outlet (figure 3). When *P. aeruginosa* was detected in the wet environment (eg, shower rosettes and drains) these genotypes were most often identical to those found in water, indicating that the water was likely the ultimate source of that clone. Genotypic variation was seen between outlets within the same room. For example, tap water sampled from room 11 had a distinct genotype from that sampled from shower water in the same room and this was consistently found over multiple samplings. Notably, isolates from two patients fell within the cluster originating from shower water, indicating that shower hydrotherapy was the most likely source of infection. Two plasmids (designated pBURNS1 and pBURNS2) were detected in this study set, which both demonstrated geographical clustering, with pBURNS1 only being detectable in isolates from room 8 and pBURNS2 only being detectable in isolates from the shower water in room 9.

Rapid evolution of antibiotic resistance associated with treatment

P. aeruginosa is commonly associated with antibiotic resistance due to a number of predisposing features including intrinsic resistance, a repertoire of efflux pumps and antibiotic-inactivating enzymes including β -lactamases.⁴¹ Three infected patients (2, 3 and 5) received antibiotic therapy, and in each case this was associated with the development of resistance to at least one therapeutic agent. Associated mutations were detected that were either partially or fully explanatory of the phenotype (online supplementary appendix 12).

Patient 2 was treated with ciprofloxacin, nitrofurantoin and vancomycin (see online supplementary appendix 11 for full details). Eight of 21 (38%) tested isolates from this patient were ciprofloxacin resistant. Seven of eight isolates (88%) of the ciprofloxacin-resistant strains were distinguishable from the other isolates by a single SNP in *mexS* (annotated as PA2491 in *P. aeruginosa* PAO1; see online supplementary appendix 1 and 7). This SNP was predicted to result in a non-synonymous amino acid substitution. Disruption of this gene has been shown to cause increased expression of the *mexEF-oprN* multidrug efflux pump, associated with resistance to quinolones.⁴²




Figure 2 A schematic view of the 300-day study of *Pseudomonas aeruginosa* in a burns centre and critical care unit. Time in days is shown along the x axis with bed numbers in the critical care unit and burns unit along the y axis. Each circular icon indicates a positive isolate of *P. aeruginosa*. The icon's logotype indicates which environment it originated from (wound, urine/sputum, environment or water). The filled colour of the icon indicates the clade it belongs to. Patient icons represent the enrolment of a screening patient into the study and their location. Patient movements around the hospital are noted by dotted lines. The five patients infected with *P. aeruginosa* are denoted by rounded boxes. Boxes are coloured according to the patient number. In the event two or more isolates of the same source and clade were collected on the same day, these have been collapsed into a single circular icon.

Patient 3 was not treated with antibiotics, but isolates associated with this patient demonstrated differences in resistance to timentin and piperacillin-tazobactam. These changes were associated with non-synonymous mutations in *gacA*, the response regulator of the GacA/GacS two-component system and in *lasR*, a transcriptional activator required for transcription of elastase and LasA protease (online supplementary appendices 2 and 8).

Patient 4 was treated with meropenem, piperacillin/tazobactam, flucloxacillin and colistin. Five isolates collected 10–18 days after initiation of meropenem showed resistance to imipenem and intermediate resistance to meropenem (see online supplementary appendix 3 and 9). The most likely mutation responsible for this phenotype was detectable in two isolates, both of which had a frame-shift mutation in the gene coding for the membrane porin OprD.⁴³

Patient 5 had a prolonged stay in ITU and had multiple medical problems including *A. baumannii* infection and was treated with nine antibiotic agents including ciprofloxacin, meropenem and piperacillin-tazobactam. Serial isolates from this patient demonstrated the

stepwise acquisition of two mutations (online supplementary appendix 4). The first was in *nalC*, a probable repressor of the TetR/AcrR family (online supplementary appendix 10).⁴⁴ On inspection of the sequence alignment in this region, a large deletion of 196 nucleotide bases was seen compared to the reference PAO1 strain. This mutation was seen in association with full resistance to piperacillin-tazobactam, ceftazidime, aztreonam, meropenem and intermediate resistance to ciprofloxacin. This deletion is likely to result in over-expression of efflux pumps involving the *mexAB-oprM* operon.^{44 45} Ciprofloxacin resistance in a later isolate corresponded to the stepwise acquisition of a second mutation. This mutation is predicted to affect the well-studied DNA gyrase subunit A gene (*gyrA*) which is strongly associated with ciprofloxacin resistance.⁴⁶

Confirmation of *P. aeruginosa* genotypes in biofilms by whole-genome metagenomic shotgun sequencing

P. aeruginosa is able to produce and survive in biofilms. Plumbing parts such as flow straighteners, shower rosettes,




Figure 3 The high-resolution phylogenetic reconstruction of Clade E isolates. This demonstrates the clustering of genotypes by bed space. Patient associated samples are contained within a room 11 clade. This clade contains water samples from the shower and environmental samples from the shower, drain and trolley. The water samples from the room 11 tap are in a distinct clade, indicating the biofilm within the tap has a distinct genotype to the shower. This suggests environmental contamination was more likely to arise from contaminated shower water than tap water. Details of sampling site, days since start of study and presence of pBURNS plasmids are also shown. The likely phylogenetic position of *Pseudomonas aeruginosa* detected in a biofilm from a thermostatic mixer valve is shown in the clade associated with room 9 and indicated 'TMV'.

flexible hoses, solenoid valves and thermostatic mixer valves (TMV) are particularly at risk of biofilm formation due to factors including surface areas, convoluted designs and inadequate pasteurisation.⁴⁷ To confirm the presence of *P. aeruginosa* in water fittings associated with rooms on the burns unit, we obtained a TMV removed by the hospital estates team from the shower in room nine as part of compliance with UK guidelines for managing *P. aeruginosa*

in hospitals. On visual inspection, a biofilm was present which was scraped from the surface with a sterile scalpel. DNA from this biofilm was extracted for whole-genome shotgun sequencing. The majority of reads did not map to any known bacterial taxa. The most abundant taxon identified was *P. aeruginosa* (3%). Subsequent alignment to the *P. aeruginosa* Clade E reference covered 94% of the 6.3 million base reference genome at a median coverage of

5×, confirming that reads were correctly classified to this species and not other environmental *Pseudomonas* species. Alignment to the *P. aeruginosa* Clade E reference genome followed by phylogenetic placement of reads demonstrated that it fell into the same clade as previously recovered isolates from the shower or tap in room 9 (indicated on figure 3, and in online supplementary appendix 6).

DISCUSSION

The hospital environment has been intimately linked with *P. aeruginosa* infection for over 50 years yet hospital acquisitions, clusters and outbreaks remain a common occurrence and understanding precise routes of transmission can be difficult.^{47 48} Our results demonstrate that, even in a new hospital, *P. aeruginosa* can become rapidly endemic in hospital plumbing. Furthermore, by linking *P. aeruginosa* genotypes recovered from patients to specific individual water outlets, we offer compelling evidence of unidirectional transmission from water to patients. Further, by sequencing of a biofilm identified in a TMV from a hospital water system, we can identify the likely common source of genotypes found in water and in the hospital environment.

Our results suggest that use of WGS can reduce ambiguity about potential transmission events in hospitals and consequently inform infection prevention efforts about the direction and sequence of transmission. Typing schemes such as MLST and PFGE are much lower resolution methods and would not be able to provide sufficient information to permit such inferences to be made. It is notable that the burns unit was colonised by a single clone, meaning that it was very unlikely that water outlets at each bed space were colonised as a result of transmissions from the patient or environment. For this to happen would require multiple transmission events from separate patients with the same clone, for which there is no evidence. Instead we speculate that this clone was introduced to the hospital associated with its commissioning. One hypothesis is that particular plumbing fittings, that is, the TMV may have been colonised simultaneously by a clone circulating in water. Clade E (ST395) has been frequently reported associated with water, so this remains a possibility.^{49 50} However, it is possible that plumbing fittings are installed 'pre-seeded' with *P. aeruginosa* as has already been proposed by Kelsey.^{3 5 47} Investigation of an outbreak in Wales implicated new plumbing parts as a potential source of *P. aeruginosa*. New plumbing components are often tested by companies prior to their supply and it is possible they were contaminated prior to distribution. The limited amount of diversity (average 4 SNPs) seen within this clade is consistent with a single founding genotype coinciding with the opening of the burns unit, based on estimates from a previous study using WGS which reported that mutations accumulate at a rate of approximately one every 3–4 months in a hospital-associated clone.⁵¹ However, our results suggest

that our isolates accumulate mutations even more slowly. This may be due to reduced growth rates in nutritionally-poor biofilms.⁵²

It is notable that antibiotic resistance to multiple first-line agents developed rapidly in response to therapy. These results underline the importance of selecting appropriate antibiotic therapy in *P. aeruginosa* infections. It is reassuring however that antibiotic resistance genotypes selected *in vivo* did not show evidence of persistence in the ward environment or transmission to other patients.

Our study has certain limitations. Based on a previous audit, we expected around one-third of patients screened for *P. aeruginosa* would develop colonisation or clinical infection. In fact, only 5 out of 30 of patients were colonised. This may have been related to guidance and engineering interventions being put in place during the study as detailed in national guidance issued while this study was on-going. In addition, infection control policies were revised to address control of an outbreak of a multidrug resistant *A. baumannii* in this same burns unit. Following these interventions, only 1 of the last 20 patients recruited was infected with *P. aeruginosa* which may demonstrate the importance of national guidance in reducing transmissions.

By focusing on burns patients who receive hydrotherapy, our study population were at extremely high risk of waterborne infection. In other patient groups it may be that alternative routes of transmission including cross-infection or endogenous carriage play a more important role. Our results suggest that our burns unit is endemically colonised with a distinct clone of *P. aeruginosa* that may have been imported coinciding with the opening of the hospital. Other intensive care units, particularly those which have been open for longer may harbour a greater diversity of *P. aeruginosa* as a result of increased opportunities for clones to be imported.

One potential application for WGS in infection control would be to determine whether cases are as a result of water transmission, or represent sporadic clones originating from the wider environment. Despite improved guidance concerning improved engineering infection control practices and the introduction of the water safety group in the UK, it may not be realistic to eliminate *P. aeruginosa* from hospitals entirely. In augmented care units such as ITUs, burns units and neonatal wards where *P. aeruginosa* poses a significant risk to vulnerable patients, the increased resolution offered by WGS will justify its use, particularly as the costs continue to fall.

In conclusion, we have identified through WGS clear evidence for transmission of *P. aeruginosa* from specific water outlets to burns patients and offer a forensic-level framework for dealing with outbreaks linked to hospital water. We expect WGS will continue to make inroads into clinical microbiology and become a vital tool for tracking *P. aeruginosa* in the hospital environment, helping inform targeted control measures to help protect patients at risk of infection.

Author affiliations

¹Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK

²NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, Birmingham, UK

³Healing Foundation Centre for Burns Research, University Hospital Birmingham Foundation Trust, Birmingham, UK

⁴Division of Microbiology and Immunology, University of Warwick, Warwick, UK

Acknowledgements The authors are grateful to Mark Webber for discussions on antibiotic resistance and to Paul Keim for discussion on phylogenetic placement of metagenomics samples. The authors thank Lex Nederbragt, Ave Tooming-Klunderud and the staff of the Norwegian Sequencing Centre, Oslo for Pacific Biosciences sequencing. The authors thank Matthew Smith-Banks for laboratory assistance with processing samples. The authors also thank Jimmy Walker for critical reading of the manuscript. The authors also thank Drs David Baltrus, Thomas Connor, Jennifer Gardy and Alan McNally for their helpful comments and suggestions to help improve the manuscript made during the open peer review process.

Contributors MJP, NSM and BO conceived the study. CMW and AB enrolled patients into study and collected samples. NC collected environmental and water samples. NC, CC and MN processed samples and performed microbiology. NC, CC and JQ did sequencing. JQ, NC, CMT and NJL analysed the data. NJL, NC, JQ, MJP and BO wrote the paper. All authors commented on the manuscript draft.

Funding This paper presents independent research funded by the National Institute for Health research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. NJL is funded by a Medical Research Council Special Training Fellowship in Biomedical Informatics.

Competing interests None.

Ethics approval The study protocol received approval from National Research Ethics Service committee in the West Midlands (reference number 12/WM/0181).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Pacific Biosciences raw data files are available from the corresponding author (Nicholas J Loman, n.j.loman@bham.ac.uk).

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Reuter S, Sigge A, Wiedeck H, *et al.* Analysis of transmission pathways of *Pseudomonas aeruginosa* between patients and tap water outlets. *Crit Care Med* 2002;30:2222–8.
2. Struelens MJ, Rost F, Deplano A, *et al.* *Pseudomonas aeruginosa* and Enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. *Am J Med* 1993;95:489–98.
3. DiazGranados CA, Jones MY, Kongphet-Tran T, *et al.* Outbreak of *Pseudomonas aeruginosa* infection associated with contamination of a flexible bronchoscope. *Infect Control Hosp Epidemiol* 2009;30:550–5.
4. Crivaro V, Di Popolo A, Caprio A, *et al.* *Pseudomonas aeruginosa* in a neonatal intensive care unit: molecular epidemiology and infection control measures. *BMC Infect Dis* 2009;9:70.
5. Moolenaar RL, Crutcher JM, San Joaquin VH, *et al.* A prolonged outbreak of *Pseudomonas aeruginosa* in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? *Infect Control Hosp Epidemiol* 2000;21:80–5.
6. Trautmann M, Lepper PM, Haller M. Ecology of *Pseudomonas aeruginosa* in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. *Am J Infect Control* 2005;33: S41–9.
7. Foca M, Jakob K, Whittier S, *et al.* Endemic *Pseudomonas aeruginosa* infection in a neonatal intensive care unit. *N Engl J Med* 2000;343:695–700.
8. Kolmos HJ, Thuesen B, Nielsen SV, *et al.* Outbreak of infection in a burns unit due to *Pseudomonas aeruginosa* originating from contaminated tubing used for irrigation of patients. *J Hosp Infect* 1993;24:11–21.
9. Widmer AF, Wenzel RP, Trilla A, *et al.* Outbreak of *Pseudomonas aeruginosa* infections in a surgical intensive care unit: probable transmission via hands of a health care worker. *Clin Infect Dis* 1993;16:372–6.
10. Srinivasan A, Wolfenden LL, Song X, *et al.* An outbreak of *Pseudomonas aeruginosa* infections associated with flexible bronchoscopes. *N Engl J Med* 2003;348:221–7.
11. Wise J. Three babies die in pseudomonas outbreak at Belfast neonatal unit. *BMJ* 2012;344:e592.
12. Breathnach AS, Cubbon MD, Karunaharan RN, *et al.* Multidrug-resistant *Pseudomonas aeruginosa* outbreaks in two hospitals: association with contaminated hospital waste-water systems. *J Hosp Infect* 2012;82:19–24.
13. Walker JT, Jhutti A, Parks S, *et al.* Investigation of healthcare-acquired infections associated with *Pseudomonas aeruginosa* biofilms in taps in neonatal units in Northern Ireland. *J Hosp Infect* 2014;86:16–23.
14. Health Technical Memorandum 04-01: Addendum. Department of Health https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/140105/Health_Technical_Memorandum_04-01_Addendum.pdf (accessed 11 Dec 2013).
15. Maiden MC, Bygraves JA, Feil E, *et al.* Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci USA* 1998;95:3140–5.
16. Jefferies JMC, Cooper T, Yam T, *et al.* *Pseudomonas aeruginosa* outbreaks in the neonatal intensive care unit—a systematic review of risk factors and environmental sources. *J Med Microbiol* 2012;61:1052–61.
17. Cholley P, Thouverez M, Hocquet D, *et al.* Most multidrug-resistant *Pseudomonas aeruginosa* isolates from hospitals in eastern France belong to a few clonal types. *J Clin Microbiol* 2011;49:2578–83.
18. Curran B, Jonas D, Grundmann H, *et al.* Development of a multilocus sequence typing scheme for the opportunistic pathogen *Pseudomonas aeruginosa*. *J Clin Microbiol* 2004;42:5644–9.
19. Harris SR, Cartwright EJP, Török ME, *et al.* Whole-genome sequencing for analysis of an outbreak of methicillin-resistant *Staphylococcus aureus*: a descriptive study. *Lancet Infect Dis* 2013;13:130–6.
20. Lewis T, Loman NJ, Bingle L, *et al.* High-throughput whole-genome sequencing to dissect the epidemiology of *Acinetobacter baumannii* isolates from a hospital outbreak. *J Hosp Infect* 2010;75:37–41.
21. Snitkin ES, Zelazny AM, Thomas PJ, *et al.* Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Sci Transl Med* 2012;4:148ra116.
22. Loman NJ, Misra RV, Dallman TJ, *et al.* Performance comparison of benchtop high-throughput sequencing platforms. *Nat Biotechnol* 2012;30:434–9.
23. Tredget EE, Shankowsky HA, Joffe AM, *et al.* Epidemiology of infections with *Pseudomonas aeruginosa* in burn patients: the role of hydrotherapy. *Clin Infect Dis* 1992;15:941–9.
24. Langschmidt J, Caine PL, Wearn CM, *et al.* Hydrotherapy in burn care: a survey of hydrotherapy practices in the UK and Ireland and literature review. *Burns* 2014;40:860–4.
25. Tredget EE, Shankowsky HA, Rennie R, *et al.* *Pseudomonas* infections in the thermally injured patient. *Burns* 2004;30:3–26.
26. Davison PG, Loiselle FB, Nickerson D. Survey on current hydrotherapy use among North American burn centers. *J Burn Care Res* 2010;31:393–9.
27. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–20.
28. Stewart L, Ford A, Sangal V, *et al.* Draft genomes of 12 host-adapted and environmental isolates of *Pseudomonas aeruginosa* and their positions in the core genome phylogeny. *Pathog Dis* 2014;71:20–5.
29. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010;26:589–95.
30. Koboldt DC, Zhang Q, Larson DE, *et al.* VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* 2012;22:568–76.
31. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. *PLoS ONE* 2010;5: e9490.


32. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. *Genome Res* 2008;18:821–9.
33. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. *BMC Bioinformatics* 2010;11:595–5.
34. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol* 2014;15:R46.
35. Matsen FA, Kodner RB, Armbrust EV. pplacer: linear time maximum-likelihood and Bayesian phylogenetic placement of sequences onto a fixed reference tree. *BMC Bioinformatics* 2010;11:538.
36. Scott FW, Pitt TL. Identification and characterization of transmissible *Pseudomonas aeruginosa* strains in cystic fibrosis patients in England and Wales. *J Med Microbiol* 2004;53:609–15.
37. Panagea S, Winstanley C, Parsons YN, et al. PCR-based detection of a cystic fibrosis epidemic strain of *Pseudomonas Aeruginosa*. *Mol Diagn* 2003;7:195–200.
38. Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. *N Engl J Med* 2011;364:730–9.
39. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of *Mycobacterium abscessus* between patients with cystic fibrosis: a retrospective cohort study. *Lancet* 2013;381:1551–60.
40. Lienau EK, Strain E, Wang C, et al. Identification of a salmonellosis outbreak by means of molecular sequencing. *N Engl J Med* 2011;364:981–2.
41. Lambert PA. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. *J R Soc Med* 2002;95(Suppl 41):22–6.
42. Sobel ML, Neshat S, Poole K. Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of *Pseudomonas aeruginosa*. *J Bacteriol* 2005;187:1246–53.
43. Quinn JP, Dudek EJ, DiVincenzo CA, et al. Emergence of resistance to imipenem during therapy for *Pseudomonas aeruginosa* infections. *J Infect Dis* 1986;154:289–94.
44. Cao L, Srikumar R, Poole K. MexAB-OprM hyperexpression in NalC-type multidrug-resistant *Pseudomonas aeruginosa*: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. *Mol Microbiol* 2004;53:1423–36.
45. Llanes C, Hocquet D, Vagne C, et al. Clinical strains of *Pseudomonas aeruginosa* overproducing MexAB-OprM and MexXY efflux pumps simultaneously. *Antimicrob Agents Chemother* 2004;48:1797–802.
46. Cambau E, Perani E, Dib C, et al. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of *Pseudomonas aeruginosa* susceptible or resistant to imipenem. *Antimicrob Agents Chemother* 1995;39:2248–52.
47. Kelsey M. *Pseudomonas* in augmented care: should we worry? *J Antimicrob Chemother* 2013;68:2697–700.
48. Rogers DE. The changing pattern of life-threatening microbial disease. *N Engl J Med* 1959;261:677–83.
49. Martin K, Baddal B, Mustafa N, et al. Clusters of genetically similar isolates of *Pseudomonas aeruginosa* from multiple hospitals in the UK. *J Med Microbiol* 2013;62:988–1000.
50. Slekovec C, Plantin J, Cholley P, et al. Tracking down antibiotic-resistant *Pseudomonas aeruginosa* isolates in a wastewater network. *PLoS ONE* 2012;7:e49300.
51. Snyder LA, Loman N, Faraj LA, et al. Epidemiological investigation of *Pseudomonas aeruginosa* isolates from a six-year-long hospital outbreak using high-throughput whole genome sequencing. *Euro Surveill* 2013;17, 18:pii: 20611.
52. Donlan RM. Biofilm formation: a clinically relevant microbiological process. *Clin Infect Dis* 2001;33:1387–92.

Online appendix 1


0.94	922	P02	BCU	8	Wound swab	Upper back	40	R	I	I	S	I	S	S	S	S	S	S	S
	921	P02	BCU	8	Wound swab	Upper back	40												
0.93	913	P02	BCU	8	Environmental	Shower trolley	40	R	S	S	S	I	S	S	S	S	S	S	S
	919	P02	BCU	8	Wound swab	Chest	40	R	I	I	S	I	I	S	S	S	S	R	S
	926	P02	BCU	8	Wound swab	Right palm	44	R	I	I	S	I	I	S	S	S	S	R	S
	909	P02	BCU	8	Wound swab	Anterior left upper-arm	37	R	I	I	S	I	R	S	S	S	S	R	S
	908	P02	BCU	8	Wound swab	Anterior left upper-arm	37	R	I	I	S	I	S	S	S	S	S	S	S
	925	P02	BCU	8	Wound swab	Anterior left upper-arm	44	R	I	I	S	I	I	S	S	S	S	R	S
	932	P02	BCU	8	Wound swab	Back of head	49	R	I	I	S	I	R	S	S	S	S	R	S
	928	P02	BCU	8	Wound swab	Upper back	44	R	I	I	S	I	I	I	S	S	S	R	S
	927	P02	BCU	8	Wound swab	Upper back	44	R	I	I	S	I	I	I	S	S	S	R	S
	915	P02	BCU	8	Environmental	Chair	40	R	I	I	S	I	S	S	S	S	S	S	S
	914	P02	BCU	8	Environmental	Chair	40	R	S	S	S	I	S	S	S	S	S	S	S
	904	P02	BCU	8	Tissue	Anterior right upper-arm	33	R	S	S	S	I	S	S	S	S	S	S	S
	905	P02	BCU	8	Wound swab	Chest	37	R	I	I	S	I	I	S	S	S	S	S	S
	906	P02	BCU	8	Wound swab	Chest	37	R	I	I	S	I	I	S	S	S	S	S	S
	920	P02	BCU	8	Wound swab	Chest	40	R	I	I	S	I	R	I	S	S	S	R	S
	918	P02	BCU	8	Wound swab	Chest	40	R	I	I	S	I	S	S	S	S	S	S	S
	907	P02	BCU	8	Wound swab	Abdomen	37	R	I	I	S	I	S	S	S	S	S	S	S
	911	P02	BCU	8	Wound swab	Anterior left forearm	37	R	I	I	S	I	I	S	S	S	S	S	S
	912	P02	BCU	8	Wound swab	Anterior left forearm	37	R	I	I	S	I	I	S	S	S	S	S	S
	923	P02	BCU	8	Wound swab	Posterior left upper-arm	40	R	I	I	S	I	S	S	S	S	S	S	S

1 SNP/Indel

Online appendix 2




Online appendix 3



Sample Number	Patient	Ward	Bed	Type of Specimen	Site	Days	TIM	PIP	TAZ	CAZ	AZT	IMI	MER	AMI	GEN	TOB	CIP	COL	pBURNS1	pBURNS2
1067	SP30	BCU	12	Water	Shower (Pre-flush)	292														
1068	SP30	BCU	12	Water	Shower (Pre-flush)	292														
991	Water sampling	BCU	10	Water	Shower (Pre-flush)	90														
966	SP08	BCU	10	Water	Shower (Unknown)	65	R	S	S	S	I	S	S	S	S	S	S	S		
931	P02	BCU	8	Environmental	Shower (Rose)	49	R	S	S	S	I	S	S	S	S	S	S	S		
1065	SP30	BCU	12	Environmental	Shower (Rose)	292														
1034	SP15	BCU	8	Environmental	Shower (Rose)	176	R	S	S	S	R	S	S	S	S	S	S	S	Yes	
902	P01	BCU	11	Environmental	Drain	27														
903	P01	BCU	11	Water	Shower (Post-flush)	27	R	S	S	S	I	S	S	S	S	S	S	S		
981	P04	BCU	11	Environmental	Drain	89	R	S	S	S	I	S	S	S	S	S	S	S		
980	P04	BCU	11	Environmental	Shower (Rose)	89	R	S	S	S	I	S	S	S	S	S	S	S		
1048	SP20	BCU	11	Environmental	Shower (Rose)	216	R	S	S	S	I	S	S	S	S	S	S	S		
901	P01	BCU	11	Environmental	Trolley	27	R	S	S	S	I	S	S	S	S	S	S	S		
987	P04	BCU	11	Water	Shower (Hose)	89	R	S	S	S	I	S	S	S	S	S	S	S		
1050	SP21	BCU	11	Water	Shower (Post-flush)	216														
988	P04	BCU	11	Water	Shower (Pre-flush)	89	R	S	S	S	I	S	S	S	S	S	S	S		
968	SP10	BCU	11	Water	Shower (Unknown)	65	R	S	S	S	I	S	S	S	S	S	S	S		
900	P01	BCU	11	Wound swab	Groin	14	R	S	S	S	I	S	S	S	S	S	S	S		
979	P04	BCU	11	Wound swab	Anterior right thigh	82	R	S	S	S	I	S	S	S	S	S	S	S		
1008	P04	BCU	11	Wound swab	Anterior right thigh	103	R	S	S	S	I	S	S	S	S	S	S	S		
976	P04	BCU	11	Wound swab	Anterior right shin	72	R	S	S	S	I	S	S	S	S	S	S	S		
984	P04	BCU	11	Wound swab	Dorsum of left foot	85	R	S	S	S	I	R	I	S	S	S	S	S		
983	P04	BCU	11	Wound swab	Dorsum of left foot	85	R	S	S	S	I	R	I	S	S	S	S	S		
982	P04	BCU	11	Wound swab	Dorsum of left foot	85	R	S	S	S	I	S	S	S	S	S	S	S		
1007	P04	BCU	11	Wound swab	Anterior right thigh	93	R	S	S	S	I	R	I	S	S	S	S	S		
1009	P04	BCU	11	Wound swab	Anterior right thigh	103	R	S	S	S	I	S	S	S	S	S	S	S		
1005	P04	BCU	11	Wound swab	Anterior right thigh	91	R	S	S	S	I	R	I	S	S	S	S	S		
1006	P04	BCU	11	Wound swab	Anterior right thigh	91	R	S	S	S	I	R	I	S	S	S	S	S		
1052	SP22	BCU	9	Water	Shower (Hose)	226														Yes
993	Water sampling	BCU	9	Water	Shower (Hose)	90	R	S	S	S	I	S	S	S	S	S	S	S		
994	Water sampling	BCU	9	Water	Shower (Pre-flush)	90	R	S	S	S	I	S	S	S	S	S	S	S		
992	Water sampling	BCU	9	Water	Tap	90	R	S	S	S	I	S	S	S	S	S	S	S		
985	P04	BCU	11	Water	Tap	89	R	S	S	S	I	S	S	S	S	S	S	S		
986	P04	BCU	11	Water	Tap	89														
967	SP09	BCU	9	Water	Shower (Unknown)	65	R	S	S	S	I	S	S	S	S	S	S	S		Yes
1062	SP29	BCU	6	Environmental	Shower (Rose)	292														
1058	SP25	BCU	6	Environmental	Shower (Rose)	278														
1003	Water sampling	BCU	6	Water	Shower (Hose)	91														
1064	SP29	BCU	6	Water	Shower (Pre-flush)	292														
1036	SP15	BCU	6	Water	Shower (Pre-flush)	177														
1004	Water sampling	BCU	6	Water	Shower (Pre-flush)	91														
1057	SP25	BCU	6	Water	Shower (Pre-flush)	278	R	S	S	S	I	S	S	S	S	S	S	S		
1041	SP16	BCU	6	Water	Shower (Pre-flush)	190														
999	Water sampling	BCU	1	Water	Shower (Hose)	91														
1000	Water sampling	BCU	1	Water	Shower (Pre-flush)	91														
1010	SP11	BCU	8	Environmental	Sink	113	S	S	S	S	I	S	S	S	S	S	S	S	Yes	
989	Water sampling	BCU	12	Water	Shower (Hose)	89	R	S	S	S	I	S	S	S	S	S	S	S		
990	Water sampling	BCU	12	Water	Shower (Pre-flush)	89	R	S	S	S	I	S	S	S	S	S	S	S		
1040	SP16	BCU	6	Environmental	Shower (Rose)	190	R	S	S	S	I	S	S	S	S	S	S	S		
1031	SP13	BCU	8	Water	Shower (Hose)	155													Yes	
1001	Water sampling	BCU	5	Water	Tap	91														
996	Water sampling	BCU	7	Water	Shower (Pre-flush)	90	R	S	S	S	I	S	S	S	S	S	S	S		
1029	SP12	BCU	8	Environmental	Drain	146													Yes	
933	P02	BCU	8	Environmental	EGC	49	R	S	S	S	I	S	S	S	S	S	S	S		
930	P02	BCU	8	Environmental	Shower (Rose)	49	R	S	S	S	I	R	S	S	S	S	S	S		
1028	SP12	BCU	8	Environmental	Shower (Rose)	146													Yes	
942	P02	BCU	8	Environmental	Shower (Rose)	55	R	S	S	S	I	S	S	S	S	S	S	S		
941	P02	BCU	8	Environmental	Shower (Rose)	55	R	S	S	S	I	S	S	S	S	S	S	S		
917	P02	BCU	8	Environmental	Shower (Rose)	40	S	S	S	S	I	S	S	S	S	S	S	S	Yes	
916	P02	BCU	8	Environmental	Shower (Rose)	40	S	S	S	S	I	S	S	S	S	S	S	S	Yes	
934	P02	BCU	8	Water	Shower (Post-flush)	49	S	S	S	S	I	S	S	S	S	S	S	S	Yes	
1030	SP12	BCU	8	Water	Shower (post-flush)	146													Yes	
1035	SP14	BCU	8	Water	Shower (Post-flush)	176													Yes	
910	P02	BCU	8	Water	Shower (Post-flush)	40	S	S	S	S	I	S	S	S	S	S	S	S	Yes	
935	P02	BCU	8	Water	Shower (Pre-flush)	49	R	S	S	S	I	S	S	S	S	S	S	S	Yes	
1046	SP19	BCU	8	Water	Shower (Pre-flush)	203														
943	P02	BCU	8	Water	Shower (Pre-flush)	55	S	S	S	S	I	S	S	S	S	S	S	S	Yes	

1 SNP/Indel


Online appendix 4




Sample Number	Patient	Ward	Bed	Type of Specimen	Site	Days	TIM	PIP	TAZ	CAZ	AZT	IMI	MER	AMI	GEN	TOB	CIP	COL
1069	Water sampling	WCCB	11	Water	Tap	301	R	S	S	S	I	R	I	S	S	S	S	S
1045	SP20	WCCB	11	Environmental	Tap handle	204												
1047	SP20	WCCB	11	Water	Tap	204	R	S	S	S	I	R	I	I	R	S	S	S
1049	P05	WCCB	11	Sputum	Sputum	221		I	I	S	I	I	I	I	R	S	S	S
1053	P05	WCCB	11	Water	Tap	231	R	I	I	S	I	R	S	S	S	S	S	S
1054	P05	WCCB ₄	11	Sputum	Sputum	229	R	R	R	R	R	R	R	I	R	S	I	S
1056	P05	WCCB	11	Sputum	Sputum	242		R	R	R	S	R	R		S	S	R	S

1 SNP/Indel

Online appendix 5





Bed	Type of Specimen	Alignment
11	Shower	T CCT ACTCC - C ACAG ACCTAAC CT - - - - - G - - ACCGAAATCCTTTTCCG - C G A GGCG
11	Shower	T CCT ACTCC - T ACAG ACCTAAC CT - - - - - G - - ACCGAAATCCTTTTCCG - C G A GGCG
9	Tap	T GCA ACTCC - C ACAG ACCTAAC GT - - - - - G - - ACCGAAATCCTTTTCCG - C G C GGCG
9	TMV	T GCA - CT - C - C ACAG A - - - AAC GT - - - - - G - - ACCG - - A - CCTTTTC - G - C - - GGCG
11	Tap	T GTA ACTCC - C ACAG ACCTAAC GT - - - - - G - - ACCGAAATCCTTTTCCG - C G C GGCG
8	Shower	T CCA ACTCC - C ACAG ACCTAAC GT - - - - - G - - ACCGAAATCCTTTTCCG - C T C GGCG
6	Shower	T CCA ACTCC - C ACAG C CCTAAC GT - - - - - G - - ACCGAAATCCTTTTCCG - C T C GGCG

Chromosome	Position	Ref	Alt	Mean depth	No calls	Hom calls	Het calls	Effect	Effect impact	Functional class	Codon change	Amino acid change	Gene name	904	905	906	907	908	909	911	912	913	914	915	918	919	920	921	922	923	925	926	927	928	932
NC_002516	1558800	CCATATG	C	40	0	1	0	CODON_DELETION	MODERATE		catatg/-	HM211-	lasR																	C					
NC_002516	2806409	G	A	23	0	8	0	NON_SYNONYMOUS_CODING	MODERATE	MISSENSE	Cac/Tac	H321Y	PA2491						A	A					A						A	A	A	A	A
NC_002516	3804666	GCTTGC	G	19	0	1	0	FRAME_SHIFT	HIGH		-	-72	PA3399														G								
NC_002516	4148397	A	T	21	0	1	0	NON_SYNONYMOUS_CODING	MODERATE	MISSENSE	aTt/aAt	I181N	wspD									T													

Online appendix 8

[illegible]

Year	Month	Day	Time	Location	Activity	Duration	Frequency	Intensity	Notes	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
------	-------	-----	------	----------	----------	----------	-----------	-----------	-------	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------

Chromosome	Position	Ref	Alt	Mean depth	No calls	Hom calls	Het calls	Effect	Effect impact	Functional class	Codon change	Amino acid change	Gene name	1045	1047	1049	1053	1054	1056	1069
NC_002516	3558951	G	A	35	0	1	0	NON_SYNONYMOUS_CODING	MODERATE	MISSENSE	aCc/aTc	T83I	gyrA						A	
NC_002516	4166773	A	G	22	0	2	0	NON_SYNONYMOUS_CODING	MODERATE	MISSENSE	Acg/Gcg	T86A	nalC					G		G

Patient	Antibiotic/antifungal	Start	End	Start	End
2	Ciprofloxacin	16/10/2012	06/11/2012		
	Nitrofurantoin	16/10/2012	11/11/2012		
	Vancomycin	29/10/2012	03/11/2012		
4	Flucloxacillin	23/11/2012	30/11/2012		
	Piperacillin/tazobactam	30/11/2012	03/12/2012		
	Meropenem	03/12/2012	08/12/2012		
	Colistin	15/12/2012	21/12/2012		
5	Gentamycin	12/04/2013	12/04/2013		
	Co-amoxiclav	13/04/2013	14/04/2013		
	Erthromycin	14/04/2013	21/04/2013	11/05/2013	19/05/2013
	Piperacillin/tazobactam	14/04/2013	18/04/2013		
	Meropenem	20/04/2013	08/05/2013	19/05/2013	20/05/2013
	Caspofungin	26/04/2013	14/05/2013	20/05/2013	21/05/2013
	Linezolid	01/05/2013	12/05/2013		
	Ciprofloxacin	06/05/2013	16/05/2013	20/05/2013	21/05/2013
	Colistin	20/05/2013	23/05/2013		

Gene	Mutation type	Effect	AA substitution	Resistance phenotype	Samples
gyrA	SNP	non-synonymous	T83I	Ciprofloxacin	1056
nalC	indel	-	-	Meropenem	1054, 1056
mexS	SNP	non-synonymous	H321Y	Ciprofloxacin	908, 909, 919, 925-928, 932
oprD	indel	frame shift	-400?	Imipenem/meropenem	1005, 1006